361 related articles for article (PubMed ID: 15661498)
1. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases.
Cui Z; Lockman PR; Atwood CS; Hsu CH; Gupte A; Allen DD; Mumper RJ
Eur J Pharm Biopharm; 2005 Feb; 59(2):263-72. PubMed ID: 15661498
[TBL] [Abstract][Full Text] [Related]
2. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease.
Rodríguez-Rodríguez C; Sánchez de Groot N; Rimola A; Alvarez-Larena A; Lloveras V; Vidal-Gancedo J; Ventura S; Vendrell J; Sodupe M; González-Duarte P
J Am Chem Soc; 2009 Feb; 131(4):1436-51. PubMed ID: 19133767
[TBL] [Abstract][Full Text] [Related]
3. Effects of clioquinol on metal-triggered amyloid-beta aggregation revisited.
Mancino AM; Hindo SS; Kochi A; Lim MH
Inorg Chem; 2009 Oct; 48(20):9596-8. PubMed ID: 19817493
[TBL] [Abstract][Full Text] [Related]
4. Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease.
Cherny RA; Barnham KJ; Lynch T; Volitakis I; Li QX; McLean CA; Multhaup G; Beyreuther K; Tanzi RE; Masters CL; Bush AI
J Struct Biol; 2000 Jun; 130(2-3):209-16. PubMed ID: 10940226
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance.
Liu G; Men P; Harris PL; Rolston RK; Perry G; Smith MA
Neurosci Lett; 2006 Oct; 406(3):189-93. PubMed ID: 16919875
[TBL] [Abstract][Full Text] [Related]
6. Metal ions differentially influence the aggregation and deposition of Alzheimer's beta-amyloid on a solid template.
Ha C; Ryu J; Park CB
Biochemistry; 2007 May; 46(20):6118-25. PubMed ID: 17455909
[TBL] [Abstract][Full Text] [Related]
7. Binding of zinc(II) and copper(II) to the full-length Alzheimer's amyloid-beta peptide.
Tõugu V; Karafin A; Palumaa P
J Neurochem; 2008 Mar; 104(5):1249-59. PubMed ID: 18289347
[TBL] [Abstract][Full Text] [Related]
8. Copper(I) and copper(II) inhibit Aβ peptides proteolysis by insulin-degrading enzyme differently: implications for metallostasis alteration in Alzheimer's disease.
Grasso G; Pietropaolo A; Spoto G; Pappalardo G; Tundo GR; Ciaccio C; Coletta M; Rizzarelli E
Chemistry; 2011 Feb; 17(9):2752-62. PubMed ID: 21274957
[TBL] [Abstract][Full Text] [Related]
9. Copper complexing decreases the ability of amyloid beta peptide to cross the BBB and enter brain parenchyma.
Mare S; Penugonda S; Robinson SM; Dohgu S; Banks WA; Ercal N
Peptides; 2007 Jul; 28(7):1424-32. PubMed ID: 17580097
[TBL] [Abstract][Full Text] [Related]
10. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.
Ritchie CW; Bush AI; Mackinnon A; Macfarlane S; Mastwyk M; MacGregor L; Kiers L; Cherny R; Li QX; Tammer A; Carrington D; Mavros C; Volitakis I; Xilinas M; Ames D; Davis S; Beyreuther K; Tanzi RE; Masters CL
Arch Neurol; 2003 Dec; 60(12):1685-91. PubMed ID: 14676042
[TBL] [Abstract][Full Text] [Related]
11. Chapter 5 - Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease.
Liu G; Men P; Perry G; Smith MA
Prog Brain Res; 2009; 180():97-108. PubMed ID: 20302830
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, characterization, and metal coordinating ability of multifunctional carbohydrate-containing compounds for Alzheimer's therapy.
Storr T; Merkel M; Song-Zhao GX; Scott LE; Green DE; Bowen ML; Thompson KH; Patrick BO; Schugar HJ; Orvig C
J Am Chem Soc; 2007 Jun; 129(23):7453-63. PubMed ID: 17511455
[TBL] [Abstract][Full Text] [Related]
13. Metal Ions in Alzheimer's Disease: A Key Role or Not?
Liu Y; Nguyen M; Robert A; Meunier B
Acc Chem Res; 2019 Jul; 52(7):2026-2035. PubMed ID: 31274278
[TBL] [Abstract][Full Text] [Related]
14. Soluble amyloid beta1-28-copper(I)/copper(II)/Iron(II) complexes are potent antioxidants in cell-free systems.
Baruch-Suchodolsky R; Fischer B
Biochemistry; 2008 Jul; 47(30):7796-806. PubMed ID: 18598056
[TBL] [Abstract][Full Text] [Related]
15. The transition metals copper and iron in neurodegenerative diseases.
Rivera-Mancía S; Pérez-Neri I; Ríos C; Tristán-López L; Rivera-Espinosa L; Montes S
Chem Biol Interact; 2010 Jul; 186(2):184-99. PubMed ID: 20399203
[TBL] [Abstract][Full Text] [Related]
16. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease.
Roney C; Kulkarni P; Arora V; Antich P; Bonte F; Wu A; Mallikarjuana NN; Manohar S; Liang HF; Kulkarni AR; Sung HW; Sairam M; Aminabhavi TM
J Control Release; 2005 Nov; 108(2-3):193-214. PubMed ID: 16246446
[TBL] [Abstract][Full Text] [Related]
17. Neurotherapeutic applications of nanoparticles in Alzheimer's disease.
Sahni JK; Doggui S; Ali J; Baboota S; Dao L; Ramassamy C
J Control Release; 2011 Jun; 152(2):208-31. PubMed ID: 21134407
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic treatments for Alzheimer's disease based on metal bioavailability.
Crouch PJ; Barnham KJ; Bush AI; White AR
Drug News Perspect; 2006 Oct; 19(8):469-74. PubMed ID: 17160147
[TBL] [Abstract][Full Text] [Related]
19. Gold nanoparticle-capped mesoporous silica-based H
Yang L; Yin T; Liu Y; Sun J; Zhou Y; Liu J
Acta Biomater; 2016 Dec; 46():177-190. PubMed ID: 27619837
[TBL] [Abstract][Full Text] [Related]
20. Regulation of copper and iron homeostasis by metal chelators: a possible chemotherapy for Alzheimer's disease.
Robert A; Liu Y; Nguyen M; Meunier B
Acc Chem Res; 2015 May; 48(5):1332-9. PubMed ID: 25946460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
